New York A02289 requires pharmaceutical manufacturers to notify the attorney general of agreements delaying generic drug introductions.

New York A02289, known as the manufacturer disclosure and transparency act, mandates that pharmaceutical manufacturers notify the attorney general of any patent settlement agreements that delay the introduction of generic medications. The attorney general must then post this information on its website, making it searchable by drug, cost, disease, and manufacturer. Failure to comply with the notification requirement results in a fine of ten thousand dollars per day.

New York A02289 requires pharmaceutical manufacturers to notify the attorney general of agreements delaying generic drug introductions.

New York A02289, known as the manufacturer disclosure and transparency act, mandates that pharmaceutical manufacturers notify the attorney general of any patent settlement agreements that delay the introduction of generic medications. The attorney general must then post this information on its website, making it searchable by drug, cost, disease, and manufacturer. Failure to comply with the notification requirement results in a fine of ten thousand dollars per day.